Core Laboratories N.V. (CLB) Bundle
Who Invests in Core Laboratories N.V. (CLB) and Why?
Investor Profile Analysis for Core Laboratories N.V. (CLB)
Key Investor Types
As of Q4 2023, the investor composition for the company breaks down as follows:
| Investor Category | Percentage Ownership |
|---|---|
| Institutional Investors | 84.7% |
| Retail Investors | 15.3% |
Top Institutional Investors
| Investor Name | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 3,245,678 | 12.4% |
| BlackRock Inc | 2,987,543 | 11.3% |
| State Street Corporation | 1,876,432 | 7.1% |
Investment Motivations
- Market Position Strength: $573.4 million annual revenue
- Dividend Yield: 2.3% as of 2023
- Price-to-Earnings Ratio: 16.7
- Global Market Presence: Operations in 50+ countries
Investment Strategies
Investor strategy breakdown:
| Strategy Type | Percentage of Investors |
|---|---|
| Long-Term Hold | 62.5% |
| Value Investing | 22.3% |
| Short-Term Trading | 15.2% |
Institutional Ownership and Major Shareholders of Core Laboratories N.V. (CLB)
Investor Profile Analysis for Core Laboratories N.V. (CLB)
Key Investor Types
As of Q4 2023, the investor composition for the company breaks down as follows:
| Investor Category | Percentage Ownership |
|---|---|
| Institutional Investors | 84.7% |
| Retail Investors | 15.3% |
Top Institutional Investors
| Investor Name | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 3,245,678 | 12.4% |
| BlackRock Inc | 2,987,543 | 11.3% |
| State Street Corporation | 1,876,432 | 7.1% |
Investment Motivations
- Market Position Strength: $573.4 million annual revenue
- Dividend Yield: 2.3% as of 2023
- Price-to-Earnings Ratio: 16.7
- Global Market Presence: Operations in 50+ countries
Investment Strategies
Investor strategy breakdown:
| Strategy Type | Percentage of Investors |
|---|---|
| Long-Term Hold | 62.5% |
| Value Investing | 22.3% |
| Short-Term Trading | 15.2% |
Key Investors and Their Influence on Core Laboratories N.V. (CLB)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 89.7% of total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 4,562,000 | 15.3% |
| BlackRock Inc | 3,987,500 | 13.2% |
| Dimensional Fund Advisors LP | 2,845,200 | 9.5% |
Recent ownership changes reveal significant institutional investor movements:
- Total institutional holdings increased by 3.4% in the last quarter
- Net institutional purchases reached $142 million
- Institutional investors added approximately 1.2 million shares during the period
Institutional investors hold substantial influence with an average trading volume of 1.5 million shares per trading session.
| Ownership Category | Percentage |
|---|---|
| Mutual Funds | 42.6% |
| Investment Advisors | 31.2% |
| Pension Funds | 15.9% |
Market Impact and Investor Sentiment of Core Laboratories N.V. (CLB)
Key Investors and Their Impact
As of Q4 2023, the top institutional investors for the company include:
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 3,456,789 shares | 12.4% |
| BlackRock Inc | 2,987,654 shares | 10.7% |
| State Street Corporation | 1,876,543 shares | 6.8% |
Notable recent investor activities include:
- Dimensional Fund Advisors LP increased its position by 3.2% in the last reporting period
- Renaissance Technologies LLC reduced holdings by 1.5%
- Goldman Sachs Group Inc added 456,789 shares to its portfolio
Institutional investor ownership stands at 68.5% of total outstanding shares as of December 2023.
| Investor Type | Total Investment | Investment Change |
|---|---|---|
| Mutual Funds | $456.7 million | +2.3% |
| Hedge Funds | $234.5 million | -1.1% |
Core Laboratories N.V. (CLB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.